CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R.
Moutal A, et al.
Pain. 2017 Dec;158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002.
Pain. 2017.
PMID: 28809766
Free PMC article.